<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<Bundle xmlns="http://hl7.org/fhir">
	<type value="collection"/>
	<!-- Repeat at this level per document -->
	<entry>
		<fullUrl value="urn:uuid:6f2a6fd6-1ce5-40b3-b669-870c252cd3a6"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
            <Bundle>
            	<!-- When PUTing, some servers mandate an id here to match the existing id -->
            	<id value="54a26d1a-3f49-4539-9db2-8379836ca018"/>
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="${instance.bundle[n].Identifier}"/>
				</identifier>
				<!-- fixed code -->
				<type value="document" /> 
            	<!-- document bundles must have a date (bdl-10) -->
            	<timestamp value="2021-05-11T20:15:11Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:65081306-6505-4125-8e9f-929776db66ec"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
                        <Composition>
                        	<!-- images if requied within html text of this document -->
							
							<contained>
                                <Binary>
                                	<id value="image0"/>
                                	<!-- example format -->
                                	<contentType value="Abasaglar-h-2835-en_files/image003.gif"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Abasaglar-h-2835-en_files/image003.gif"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image0"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image1"/>
                                	<!-- example format -->
                                	<contentType value="Abasaglar-h-2835-en_files/image004.gif"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Abasaglar-h-2835-en_files/image004.gif"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image1"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image2"/>
                                	<!-- example format -->
                                	<contentType value="Abasaglar-h-2835-en_files/image005.jpg"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Abasaglar-h-2835-en_files/image005.jpg"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image2"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image3"/>
                                	<!-- example format -->
                                	<contentType value="Abasaglar-h-2835-en_files/image006.gif"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Abasaglar-h-2835-en_files/image006.gif"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image3"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image4"/>
                                	<!-- example format -->
                                	<contentType value="Abasaglar-h-2835-en_files/image007.gif"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Abasaglar-h-2835-en_files/image007.gif"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image4"/>
                        		</valueReference>
               </extension>
              
							<contained>
                                <Binary>
                                	<id value="image5"/>
                                	<!-- example format -->
                                	<contentType value="Abasaglar-h-2835-en_files/image008.jpg"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="Abasaglar-h-2835-en_files/image008.jpg"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image5"/>
                        		</valueReference>
               </extension>
              
              
              <contained>
                          <Binary>
                            <id value="stylesheet0"/>
                            <!-- example format -->
                            <contentType value="stylesheet/css"/>
                            <!-- data is base 64 encoded, actual bytes of the image png file -->
                            <data value="<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin:0in;
	page-break-after:avoid;
	background:#993366;
	font-size:14.0pt;
	font-family:"Arial",sans-serif;
	color:white;
	layout-grid-mode:line;
	font-weight:bold;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:18.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Cambria",serif;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,- H19\,Annotationtext\,Char\,Comment Text Char Char\,Comment Text Char Char Char Char\,Comment Text Char Char1\,Comment Text Char Char1 Char\,Comment Text Char1 Char\,Comment Text Char1 Char Char\,Comment Text Char2 Char\,Tekst opmerking";
	mso-style-link:"Comment Text Char\,- H19 Char\,Annotationtext Char\,Char Char\,Comment Text Char Char Char\,Comment Text Char Char Char Char Char\,Comment Text Char Char1 Char1\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char Char1\,Comment Text Char1 Char Char Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Cambria",serif;}
span.MsoCommentReference
	{mso-style-name:"Comment Reference\,Annotationmark";}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:13.0pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:.8in;
	margin-bottom:0in;
	margin-left:.8in;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#4F81BD;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
em
	{font-weight:bold;
	font-style:normal;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,- H19 Char\,Annotationtext Char\,Char Char\,Comment Text Char Char Char\,Comment Text Char Char Char Char Char\,Comment Text Char Char1 Char1\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char Char1\,Comment Text Char1 Char Char Char";
	mso-style-link:"Comment Text\,- H19\,Annotationtext\,Char\,Comment Text Char Char\,Comment Text Char Char Char Char\,Comment Text Char Char1\,Comment Text Char Char1 Char\,Comment Text Char1 Char\,Comment Text Char1 Char Char\,Comment Text Char2 Char\,Tekst opmerking";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Times New Roman",serif;}
p.PIbodytext, li.PIbodytext, div.PIbodytext
	{mso-style-name:"PI body text";
	mso-style-link:"PI body text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.PIbodytextChar
	{mso-style-name:"PI body text Char";
	mso-style-link:"PI body text";
	font-family:"Times New Roman",serif;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	font-family:"Times New Roman",serif;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Arial",sans-serif;
	color:white;
	background:#993366;
	layout-grid-mode:both;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.TableText, li.TableText, div.TableText
	{mso-style-name:"Table Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Arial",sans-serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Verdana",sans-serif;
	color:black;}
p.IFUBodyText, li.IFUBodyText, div.IFUBodyText
	{mso-style-name:"IFU Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.IFUBulletedBodyText, li.IFUBulletedBodyText, div.IFUBulletedBodyText
	{mso-style-name:"IFU Bulleted Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;}
p.IFUBulletedBodyText2, li.IFUBulletedBodyText2, div.IFUBulletedBodyText2
	{mso-style-name:"IFU Bulleted Body Text 2";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;}
p.TittleB, li.TittleB, div.TittleB
	{mso-style-name:"Tittle B";
	mso-style-link:"Tittle B Char";
	margin-top:0in;
	margin-right:6.0pt;
	margin-bottom:0in;
	margin-left:6.35pt;
	page-break-after:avoid;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
span.TittleBChar
	{mso-style-name:"Tittle B Char";
	mso-style-link:"Tittle B";
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	font-family:"Times New Roman",serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:normal;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	font-family:"Times New Roman",serif;}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	font-family:"Times New Roman",serif;}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;
	font-family:"Times New Roman",serif;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;
	font-family:"Times New Roman",serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";
	font-family:"Times New Roman",serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Times New Roman",serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Cambria",serif;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Cambria",serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Cambria",serif;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";
	font-family:"Times New Roman",serif;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;
	font-family:"Times New Roman",serif;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;
	font-family:"Times New Roman",serif;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.mdTblEntry, li.mdTblEntry, div.mdTblEntry
	{mso-style-name:"md_Tbl Entry";
	margin:0in;
	line-height:12.95pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.IFUHeading1, li.IFUHeading1, div.IFUHeading1
	{mso-style-name:"IFU Heading 1";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	layout-grid-mode:line;
	font-weight:bold;}
p.a, li.a, div.a
	{mso-style-name:a;
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.KommentarerChar
	{mso-style-name:"Kommentarer Char";}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection3
	{page:WordSection3;}
@page WordSection4
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection4
	{page:WordSection4;}
@page WordSection5
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection5
	{page:WordSection5;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>"/>
                          </Binary>
                        </contained>
                        <!-- this exension is necessary per image -->
                        <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                          <valueReference>
                            <reference value="#stylesheet0"/>
                          </valueReference>
                        </extension>
              
              <status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="${document[n].documentTypeCode}"/>
									<display value="${document[n].documentTypeDisplay}"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="[]"/> <!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/--> <!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
                        	<!-- mandatory date of the document -->
                        	<date value="2021-02-01"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations" />
									<value value="" />
								</identifier>
							</author>
                        	<title value="${document[n].title}"/>
							<relatesTo>
								<code value="appends"/>
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
	               			
<section>
	
		
			<title value="SUMMARY OF PRODUCT CHARACTERISTICS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR</span><span lang="EN-GB"> 100 units/mL solution for injection in a cartridge</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p style="margin:0in"><span lang="EN-GB" style="font-size:11.0pt">Each mL contains 100 units insulin glargine* (equivalent to 3.64 mg). </span></p><p style="margin:0in"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Each cartridge contains 3 mL of solution for injection, equivalent to 300 units. </span></p><p style="margin:0in"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">*produced by recombinant DNA technology in <i>Escherichia coli</i>. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">For the full list of excipients, see section 6.1.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Solution for injection (injection).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Clear, colourless solution.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Posology"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR contains insulin glargine, an insulin analogue and has a prolonged duration of action. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR should be administered once daily at any time but at the same time each day. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The dose regimen (dose and timing) should be individually adjusted. In patients with type 2 diabetes mellitus, ABASAGLAR can also be given together with orally active antidiabetic medicinal products. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The potency of this medicinal product is stated in units. These units are exclusive to insulin glargine and are not the same as IU or the units used to express the potency of other insulin analogues (see section 5.1). </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Special populations</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><span lang="EN-GB">Elderly population (65 years old)</span></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In the elderly, progressive deterioration of renal function may lead to a steady decrease in insulin requirements.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><i><span lang="EN-GB">Renal impairment</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><span lang="EN-GB">Hepatic impairment</span></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><span lang="EN-GB">Adolescents and children aged 2 years and older</span></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The safety and efficacy of insulin glargine have been established in adolescents and children aged 2 years and older (see section 5.1). The dose regimen (dose and timing) should be individually adjusted. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><span lang="EN-GB">Children below 2 years of age</span></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The safety and efficacy of insulin glargine have not been established No data are available. </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Switch from other insulins to ABASAGLAR</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">When switching from a treatment regimen with an intermediate or long-acting insulin to a regimen with ABASAGLAR, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast-acting insulin analogues or the dose of oral antidiabetic medicinal products). </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Switch from twice daily NPH insulin to ABASAGLAR</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with ABASAGLAR should reduce their daily dose of basal insulin by 20-30 % during the first weeks of treatment. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"><i><u><span lang="EN-GB">Switch from insulin glargine 300 units/ml to ABASAGLAR</span></u></i></p><p class="MsoNormal" style="line-height:normal"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">ABASAGLAR and Toujeo (insulin glargine 300 units/ml) are not bioequivalent and are not directly interchangeable. To reduce the risk of hypoglycemia, patients who are changing their basal insulin regimen from an insulin regimen with once daily insulin glargine 300 units/ml to a once daily regimen with ABASAGLAR should reduce their dose by approximately 20%.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">During the first weeks the reduction should, at least partially, be compensated by an increase in mealtime insulin, after this period the regimen should be adjusted individually. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">With improved metabolic control and resulting increase in insulin sensitivity a further adjustment in dose regimen may become necessary. Dose adjustment may also be required, for example, if the patient's weight or life-style changes, change of timing of insulin dose or other circumstances arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see section 4.4). </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with ABASAGLAR.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR is administered subcutaneously.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR should not be administered intravenously. The prolonged duration of action of insulin glargine is dependent on its injection into subcutaneous tissue. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">There are no clinically relevant differences in serum insulin or glucose levels after abdominal, deltoid or thigh administration of insulin glargine. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4.8).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR must not be mixed with any other insulin or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">For further details on handling, see section 6.6.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Traceability"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Diabetic ketoacidosis</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, regular insulin administered intravenously is recommended in such cases. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><a name="_Hlk38983853"><u><span lang="EN-GB">Insulin requirements and dose adjustments</span></u></a></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In case of insufficient glucose control or a tendency to hyperglycaemic or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, longacting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Hypoglycaemia</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The time of occurrence of hypoglycaemia depends on the action profile of the insulins used and may, therefore, change when the treatment regimen is changed. Due to more sustained basal insulin supply with insulin glargine, less nocturnal but more early morning hypoglycaemia can be expected.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Particular caution should be exercised, and intensified blood glucose monitoring is advisable in patients in whom hypoglycaemic episodes might be of particular clinical relevance, such as in patients with significant stenoses of the coronary arteries or of the blood vessels supplying the brain (risk of cardiac or cerebral complications of hypoglycaemia) as well as in patients with proliferative retinopathy, particularly if not treated with photocoagulation (risk of transient amaurosis following hypoglycaemia). </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Patients should be aware of circumstances where warning symptoms of hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be changed, be less pronounced or be absent in certain risk groups. These include patients:</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        in whom glycaemic control is markedly improved,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        in whom hypoglycaemia develops gradually,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        who are elderly,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        after transfer from animal insulin to human insulin,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        in whom an autonomic neuropathy is present,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        with a long history of diabetes,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        suffering from a psychiatric illness,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        receiving concurrent treatment with certain other medicinal products (see section 4.5).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Such situations may result in severe hypoglycaemia (and possibly loss of consciousness) prior to the patient's awareness of hypoglycaemia.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The prolonged effect of subcutaneous insulin glargine may delay recovery from hypoglycaemia.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">If normal or decreased values for glycated haemoglobin are noted, the possibility of recurrent, unrecognised (especially nocturnal) episodes of hypoglycaemia must be considered. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Adherence of the patient to the dose and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia. Factors increasing the susceptibility to hypoglycaemia require particularly close monitoring and may necessitate dose adjustment. These include:</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        change in the injection area,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        improved insulin sensitivity (e.g., by removal of stress factors),</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        unaccustomed, increased or prolonged physical activity,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        intercurrent illness (e.g. vomiting, diarrhoea),</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        inadequate food intake,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        missed meals,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        alcohol consumption,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        certain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or adrenocortical insufficiency),</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        concomitant treatment with certain other medicinal products.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB">Injection technique</span></u></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Intercurrent illness</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Intercurrent illness requires intensified metabolic monitoring. In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased. Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food, or are vomiting etc. and they must never omit insulin entirely. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Insulin antibodies</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see section 5.1).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Pens to be used with ABASAGLAR cartridges </span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The cartridges should only be used in conjunction with a Lilly reusable insulin pen and should not be used with any other reusable pen as the dosing accuracy has not been established with other pens. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Medication errors</span></u></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Medication errors have been reported in which other insulins, particularly shortacting insulins, have been accidentally administered instead of insulin glargine. Insulin label must always be checked before each injection to avoid medication errors between ABASAGLAR and other insulins.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Combination of ABASAGLAR with pioglitazone</span></u></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and ABASAGLAR is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB">Sodium content</span></u></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially sodiumfree.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">A number of substances affect glucose metabolism and may require dose adjustment of insulin glargine.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Substances that may enhance the blood-glucoselowering effect and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates, somatostatin anologues and sulphonamide antibiotics. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens, progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood-glucose lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Pregnancy"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Animal data do not indicate reproductive toxicity. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The use of ABASAGLAR may be considered during pregnancy, if clinically needed. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy to prevent adverse outcomes associated with hyperglycaemia. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Immediately after delivery, insulin requirements decline rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose control is essential. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Breast-feeding"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">It is unknown whether insulin glargine is excreted in human milk. No metabolic effects of ingested insulin glargine on the breastfed newborn/infant are anticipated since insulin glargine as a peptide is digested into amino acids in the human gastrointestinal tract. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Breast-feeding women may require adjustments in insulin dose and diet. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Fertility"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Animal studies do not indicate direct harmful effects with respect to fertility.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be considered whether it is advisable to drive or operate machines in these circumstances.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Summary of safety profile</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Hypoglycaemia (very common), in general the most frequent adverse reaction of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement (see section 4.4).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><u><span lang="EN-GB">Tabulated list of adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">The following related adverse reactions from clinical trials are listed below as MedDRA preferred term by system organ class and in order of decreasing incidence (very common: 1/10; common: 1/100 to &lt;1/10; uncommon: 1/1,000 to &lt;1/100; rare: 1/10,000 to &lt;1/1,000; very rare: &lt;1/10,000<span style="color:black"> and not known (cannot be estimated from the available data</span>).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:12.5pt;border-collapse:collapse;border:none" width="99%"> <tr style="height:16.75pt"> <td style="width:23.04%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="23%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal"><b><span lang="EN-GB">MedDRA system organ classes</span></b></p> </td> <td style="width:15.4%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="15%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal"><b><span lang="EN-GB">Very common</span></b></p> </td> <td style="width:12.32%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="12%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal"><b><span lang="EN-GB">Common</span></b></p> </td> <td style="width:13.84%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="13%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal"><b><span lang="EN-GB">Uncommon</span></b></p> </td> <td style="width:10.76%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="10%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal"><b><span lang="EN-GB">Rare</span></b></p> </td> <td style="width:11.66%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="11%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal"><b><span lang="EN-GB">Very rare</span></b></p> </td> <td style="width:12.96%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="12%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal"><b><span lang="EN-GB">Not known</span></b></p> </td> </tr> <tr style="height:16.3pt"> <td colspan="6" style="width:87.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Immune system disorders </span></b></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="12%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:16.75pt"> <td style="width:23.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="23%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Allergic reactions</span></p> </td> <td style="width:15.4%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:13.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:10.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="10%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">X</span></p> </td> <td style="width:11.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> </tr> <tr style="height:16.75pt"> <td colspan="6" style="width:87.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Metabolism and nutrition disorders</span></b></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="12%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:16.3pt"> <td style="width:23.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="23%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Hypoglycaemia</span></p> </td> <td style="width:15.4%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">X</span></p> </td> <td style="width:12.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:13.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:10.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="10%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:11.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> </tr> <tr style="height:16.3pt"> <td colspan="6" style="width:87.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Nervous system disorders</span></b></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="12%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:11.0pt"> <td style="width:23.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="23%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Dysgeusia</span></p> </td> <td style="width:15.4%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:13.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:10.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="10%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:11.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">X</span></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> </tr> <tr style="height:11.0pt"> <td colspan="6" style="width:87.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Eyes disorders</span></b></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="12%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td style="width:23.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="23%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Visual impairment </span></p> </td> <td style="width:15.4%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:13.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:10.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="10%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">X</span></p> </td> <td style="width:11.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> </tr> <tr style="height:5.75pt"> <td style="width:23.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="23%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Retinopathy</span></p> </td> <td style="width:15.4%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:13.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:10.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="10%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">X</span></p> </td> <td style="width:11.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> </tr> <tr style="height:5.75pt"> <td colspan="6" style="width:87.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></b></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td style="width:23.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="23%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Lipohypertrophy</span></p> </td> <td style="width:15.4%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">X</span></p> </td> <td style="width:13.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:10.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="10%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:11.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> </tr> <tr style="height:5.75pt"> <td style="width:23.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="23%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Lipoatrophy</span></p> </td> <td style="width:15.4%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:13.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">X</span></p> </td> <td style="width:10.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="10%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:11.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> </tr> <tr style="height:5.75pt"> <td style="width:23.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="23%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Cutaneous amyloidosis</span></p> </td> <td style="width:15.4%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> <td style="width:12.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> <td style="width:13.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> <td style="width:10.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="10%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> <td style="width:11.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> <td style="width:12.96%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">X</span></p> </td> </tr> <tr style="height:5.75pt"> <td colspan="6" style="width:87.04%;border-top:none;   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;   border-right:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Musculoskeletal and connective tissue disorders</span></b></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td style="width:23.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="23%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Myalgia</span></p> </td> <td style="width:15.4%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:13.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:10.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="10%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:11.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">X</span></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> </tr> <tr style="height:5.75pt"> <td colspan="6" style="width:87.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">General disorders and administration site conditions</span></b></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td style="width:23.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="23%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Injection site reactions</span></p> </td> <td style="width:15.4%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">X</span></p> </td> <td style="width:13.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:10.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="10%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:11.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> </tr> <tr style="height:5.75pt"> <td style="width:23.04%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="23%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Oedema</span></p> </td> <td style="width:15.4%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.32%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:13.84%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:10.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="10%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">X</span></p> </td> <td style="width:11.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> <td style="width:12.96%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"></p> </td> </tr> </table><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><u><span lang="EN-GB">Description of selected adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><i><u><span lang="EN-GB">Metabolism and nutrition disorders</span></u></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may be life-threatening. In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter-regulation. Generally, the greater and more rapid the decline in blood glucose, the more marked is the phenomenon of counter-regulation and its symptoms.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Immune system disorders</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Immediate-type allergic reactions to insulin are rare. Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angio-oedema, bronchospasm, hypotension and shock, and may be life-threatening.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Eyes disorders</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">A marked change in glycaemic control may cause temporary visual impairment, due to temporary alteration in the turgidity and refractive index of the lens.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy. However, intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy. In patients with proliferative retinopathy, particularly if not treated with photocoagulation, severe hypoglycaemic episodes may result in transient amaurosis.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Lipodystrophy and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">General disorders and administration site conditions</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Injection site reactions include redness, pain, itching, hives, swelling, or inflammation. Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Rarely, insulin may cause sodium retention and oedema particularly if previously poor metabolic control is improved by intensified insulin therapy.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><b></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In general, the safety profile for children and adolescents ( 18 years of age) is similar to the safety profile for adults. The adverse reaction reports received from post marketing surveillance included relatively more frequent injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) in children and adolescents ( 18 years of age) than in adults. Clinical study safety data are not available for children under 2 years.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><b></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Reporting of suspected adverse reactions"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="background: lightgrey">the national reporting system listed in </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="color:windowtext;background:lightgrey">Appendix V</span></a></span><span lang="EN-GB">.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Symptoms</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Insulin overdose may lead to severe and sometimes long-term and life-threatening hypoglycaemia. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><u><span lang="EN-GB">Management</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">Mild episodes of hypoglycaemia can usually be treated with oral carbohydrates. Adjustments in dose of the medicinal product, meal patterns, or physical activity may be needed. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Pharmacotherapeutic group: Drugs used in diabetes, insulins and analogues for injection, long-acting. ATC Code: A10AE04.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">ABASAGLAR is a biosimilar medicinal product. Detailed information is available on the website of the European Medicines Agency </span><span lang="EN-GB"><a href="http://www.ema.europa.eu"><span style="color:windowtext">http://www.ema.europa.eu</span></a></span><span lang="EN-GB">.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Mechanism of action"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH. It is completely soluble at the acidic pH of the ABASAGLAR injection solution (pH 4). After injection into the subcutaneous tissue, the acidic solution is neutralised leading to formation of micro-precipitates from which small amounts of insulin glargine are continuously released, providing a smooth, peakless, predictable concentration/time profile with a prolonged duration of action.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Insulin glargine is metabolised into 2 active metabolites M1 and M2 (see section 5.2).</span></p><p class="MsoNormal" style="line-height:normal"> </p><p class="MsoNormal" style="line-height:normal"><i><u><span lang="EN-GB">Insulin receptor binding</span></u></i></p><p class="MsoNormal" style="line-height:normal"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal"><i><span lang="EN-GB">In vitro</span></i><span lang="EN-GB"> studies indicate that the affinity of insulin glargine and its metabolites M1 and M2 for the human insulin receptor is similar to the one of human insulin.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">IGF-1 receptor binding: The affinity of insulin glargine for the human IGF-1 receptor is approximately 5 to 8-fold greater than that of human insulin (but approximately 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1 receptor with slightly lower affinity compared to human insulin.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The total therapeutic insulin concentration (insulin glargine and its metabolites) found in type 1 diabetic patients was markedly lower than what would be required for a half maximal occupation of the IGF-1 receptor and the subsequent activation of the mitogenic-proliferative pathway initiated by the IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may activate the mitogenic-proliferative pathway; however, the therapeutic concentrations found in insulin therapy, including in ABASAGLAR therapy, are considerably lower than the pharmacological concentrations required to activate the IGF-1 pathway. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Pharmacodynamic effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis and enhances protein synthesis.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In clinical pharmacology studies, intravenous insulin glargine and human insulin have been shown to be equipotent when given at the same doses. As with all insulins, the time course of action of insulin glargine may be affected by physical activity and other variables.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In euglycaemic clamp studies in healthy subjects or in patients with type 1 diabetes, the onset of action of subcutaneous insulin glargine was slower than with human NPH insulin, its effect profile was smooth and peakless, and the duration of its effect was prolonged.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The following graph shows the results from a study in patients:</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Figure 1: </span></b><b>Activity profile in patients with type</b><b>1 diabetes</b></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p align="right" class="MsoNormal" style="text-align:right;line-height:normal; page-break-after:avoid"><span style="position:absolute;z-index:251682816; left:0px;margin-left:-6px;margin-top:15px;width:652px;height:274px"><img height="274" src="#image0" width="652"/></span><span style="position:absolute;z-index:251680768;left:0px;margin-left:161px; margin-top:233px;width:159px;height:39px"><img alt="Time (h) after s.c injection" height="39" src="#image1" width="159"/></span><span lang="EN-GB"><img border="0" height="286" src="#image2" width="590"/></span></p><p class="MsoNormal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">* Determined as amount of glucose infused to maintain constant plasma glucose levels (hourly mean values)</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The longer duration of action of subcutaneous insulin glargine is directly related to its slower rate of absorption and supports once daily administration. The time course of action of insulin and insulin analogues such as insulin glargine may vary considerably in different individuals or within the same individual</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical study, symptoms of hypoglycaemia or counter-regulatory hormone responses were similar after intravenous insulin glargine and human insulin both in healthy volunteers and patients with type 1 diabetes.</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Clinical safety and efficacy</span></u></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In clinical studies, antibodies that cross-react with human insulin and insulin glargine were observed with the same frequency in both NPH-insulin and insulin glargine treatment groups.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Effects of insulin glargine (once daily) on diabetic retinopathy were evaluated in an open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography. No significant difference was seen in the progression of diabetic retinopathy when insulin glargine was compared to NPH insulin.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The ORIGIN (Outcome Reduction with Initial Glargine INtervention) study was a multicenter, randomised, 2x2 factorial design study conducted in 12,537 participants at high cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus treated with 1 antidiabetic oral agent (88% of participants). Participants were randomised (1:1) to receive insulin glargine (n=6,264), titrated to reach FPG 95 mg/dL (5.3 mM), or standard care (n=6,273).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The first co-primary efficacy outcome was the time to the first occurrence of CV death, nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary efficacy outcome was the time to the first occurrence of any of the first co-primary events, or revascularisation procedure (coronary, carotid, or peripheral), or hospitalisation for heart failure.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Secondary endpoints included all-cause mortality and a composite microvascular outcome.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Insulin glargine did not alter the relative risk for CV disease and CV mortality when compared to standard of care. There were no differences between insulin glargine and standard care for the two co-primary outcomes; for any component endpoint comprising these outcomes; for all-cause mortality; or for the composite microvascular outcome.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Mean dose of insulin glargine by study end was 0.42 U/kg. At baseline, participants had a median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9 to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care group throughout the duration of follow-up. The rates of severe hypoglycaemia (affected participants per 100 participant years of exposure) were 1.05 for insulin glargine and 0.30 for standard care group and the rates of confirmed non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard care group. Over the course of this 6-year study, 42% of the insulin glargine group did not experience any hypoglycaemia. </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At the last on-treatment visit, there was a mean increase in body weight from baseline of 1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the standard care group.</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a randomised, controlled clinical study, paediatric patients (age range 6 to 15 years) with type 1 diabetes (n=349) were treated for 28 weeks with a basal-bolus insulin regimen where regular human insulin was used before each meal. Insulin glargine was administered once daily at bedtime and NPH human insulin was administered once or twice daily. Similar effects on glycohaemoglobin and the incidence of symptomatic hypoglycaemia were observed in both treatment groups, however fasting plasma glucose decreased more from baseline in the insulin glargine group than in the NPH group. There was less severe hypoglycaemia in the insulin glargine group as well. One hundred forty three of the patients treated with insulin glargine in this study continued treatment with insulin glargine in an uncontrolled extension study with mean duration of follow-up of 2 years. No new safety signals were seen during this extended treatment with insulin glargine.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">A crossover study comparing insulin glargine plus lispro insulin to NPH plus regular human insulin (each treatment administered for 16 weeks in random order) in 26 adolescent type 1 diabetic patients aged 12 to 18 years was also performed. As in the paediatric study described above, fasting plasma glucose reduction from baseline was greater in the insulin glargine group than in the NPH group. HbA<sub>1c</sub> changes from baseline were similar between treatment groups; however blood glucose values recorded overnight were significantly higher in the insulin glargine/ lispro group than the NPH/regular group, with a mean nadir of 5.4 mM vs. 4.1 mM. Correspondingly, the incidences of nocturnal hypoglycaemia were 32 % in the insulin glargine / lispro group vs. 52 % in the NPH / regular group.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">A 24-week parallel group study was conducted in 125 children with type 1 diabetes mellitus aged 2 to 6 years, comparing insulin glargine given once daily in the morning to NPH insulin given once or twice daily as basal insulin. Both groups received bolus insulin before meals. The primary aim of demonstrating non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and there was a trend to an increase of hypoglycaemic events with insulin glargine [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)]. Glycohaemoglobin and glucose variabilities were comparable in both treatment groups. No new safety signals were observed in this trial.</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Absorption"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In healthy subjects and diabetic patients, insulin serum concentrations indicated a slower and much more prolonged absorption and showed a lack of a peak after subcutaneous injection of insulin glargine in comparison to human NPH insulin. Concentrations were thus consistent with the time profile of the pharmacodynamic activity of insulin glargine. Figure 1 above shows the activity profiles over time of insulin glargine and NPH insulin. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Insulin glargine injected once daily will reach steady state levels in 2-4 days after the first dose. </span></p><p class="MsoNormal" style="line-height:normal"> </p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Biotransformation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">After subcutaneous injection in diabetic patients, insulin glargine is rapidly metabolised at the carboxyl terminus of the Beta chain with formation of two active metabolites M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is the metabolite M1. The exposure to M1 increases with the administered dose of insulin glargine.</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with insulin glargine is principally based on exposure to M1. Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of insulin glargine.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Elimination"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">When given intravenously the elimination half-life of insulin glargine and human insulin were comparable. </span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"> </p><p style="margin:0in"><u><span lang="EN-GB" style="font-size:11.0pt">Special populations</span></u></p><p style="margin:0in"></p><p style="margin:0in"><span lang="EN-GB" style="font-size:11.0pt">In clinical studies, subgroup analyses based on age and gender did not indicate any difference in safety and efficacy in insulin glargine-treated patients compared to the entire study population.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Paediatric population</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Pharmacokinetics in children aged 2 to less than 6 years with type 1 diabetes mellitus was assessed in one clinical study (see section 5.1). Plasma trough levels of insulin glargine and its main M1 and M2 metabolites were measured in children treated with insulin glargine, revealing plasma concentration patterns similar to adults, and providing no evidence for accumulation of insulin glargine or its metabolites with chronic dosing.</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Zinc oxide</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Metacresol</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Glycerol</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Hydrochloric acid (for pH adjustment)</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Sodium hydroxide (for pH adjustment)</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Water for injections</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">This medicinal product must not be mixed with other medicinal products. </span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p style="margin:0in"><span lang="EN-GB" style="font-size:11.0pt">2 years.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Shelf life after first use </span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The medicinal product may be stored for a maximum of 28 days up to 30C and away from direct heat or direct light. Pens in use must not be stored in the refrigerator. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The pen cap must be put back on the pen after each injection in order to protect from light.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Before use</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Store in a refrigerator (2C - 8C).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Do not freeze.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Do not store ABASAGLAR next to the freezer compartment or a freezer pack.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Keep the cartridge in the outer carton in order to protect from light.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">In use </span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">For storage conditions after first opening of this medicinal product, see section 6.3.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"><b><s><span lang="EN-GB"></span></s></b></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">3 mL solution in a cartridge (type 1 colourless glass) with a plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and halobutyl rubber) with aluminium seal.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Packs of 5 and 10 cartridges. Not all pack sizes may be marketed.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal and other handling"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR must not be mixed with any other insulin or medicinal products or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Insulin pen</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The ABASAGLAR cartridges are to be used only in conjunction with a Lilly reusable insulin pen (see section 4.4). </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The pen should be used as recommended in the information provided with the device. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The instructions for using the pen must be followed carefully for loading the cartridge, attaching the needle, and administering the insulin injection. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">If the insulin pen is damaged or not working properly (due to mechanical defects) it has to be discarded, and a new insulin pen has to be used. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Cartridge</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Inspect the cartridge before use. It must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of water-like consistency. Since ABASAGLAR is a solution, it does not require re-suspension before use. Air bubbles must be removed from the cartridge before injection (see instructions for using the pen).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">To prevent the possible transmission of disease, each pen must be used by one patient only. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Empty cartridges must not be refilled and must be properly discarded. Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins (see section 4.4).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBER(S)"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">EU/1/14/944/003</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">EU/1/14/944/009</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Date of first authorisation: 9 September 2014</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Date of latest renewal: 25 July 2019</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu <br clear="all" style="page-break-before:always"/> <b>1.       NAME OF </b><b>THE MEDICINAL PRODUCT</b></span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR</span><span lang="EN-GB"> 100 units/mL KwikPen solution for injection in a pre-filled pen</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR</span><span lang="EN-GB"> 100 units/mL Tempo Pen solution for injection in a pre-filled pen</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p style="margin:0in"><span lang="EN-GB" style="font-size:11.0pt">Each mL contains 100 units insulin glargine* (equivalent to 3.64 mg). </span></p><p style="margin:0in"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Each pen contains 3 mL of solution for injection, equivalent to 300 units. </span></p><p style="margin:0in"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">* produced by recombinant DNA technology in <i>Escherichia coli</i>. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">For the full list of excipients, see section 6.1.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Solution for injection (injection) </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Clear, colourless solution.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Posology"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR contains insulin glargine, an insulin analogue and has a prolonged duration of action. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR should be administered once daily at any time but at the same time each day. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The dose regimen (dose and timing) should be individually adjusted. In patients with type 2 diabetes mellitus, ABASAGLAR can also be given together with orally active antidiabetic medicinal products. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The potency of this medicinal product is stated in units. These units are exclusive to insulin glargine and are not the same as IU or the units used to express the potency of other insulin analogues (see section 5.1). </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Special populations</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><span lang="EN-GB">Elderly population (65 years old)</span></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In the elderly, progressive deterioration of renal function may lead to a steady decrease in insulin requirements.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><i><span lang="EN-GB">Renal impairment</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><i><span lang="EN-GB">Hepatic impairment</span></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">In patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><span lang="EN-GB">Adolescents and children aged 2 years and older</span></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The safety and efficacy of insulin glargine have been established in adolescents and children aged 2 years and older (see section 5.1). The dose regimen (dose and timing) should be individually adjusted.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><span lang="EN-GB">Children below 2 years of age</span></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The safety and efficacy of insulin glargine have not been established. No data are available. </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Switch from other insulins to ABASAGLAR</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">When switching from a treatment regimen with an intermediate or long-acting insulin to a regimen with ABASAGLAR, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast-acting insulin analogues or the dose of oral antidiabetic medicinal products). </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Switch from twice daily NPH insulin to ABASAGLAR</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with ABASAGLAR should reduce their daily dose of basal insulin by 20-30 % during the first weeks of treatment.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"><i><u><span lang="EN-GB">Switch from insulin glargine 300 units/ml to ABASAGLAR</span></u></i></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">ABASAGLAR and Toujeo (insulin glargine 300 units/ml) are not bioequivalent and are not directly interchangeable. To reduce the risk of hypoglycemia, patients who are changing their basal insulin regimen from an insulin regimen with once daily insulin glargine 300 units/ml to a once daily regimen with ABASAGLAR should reduce their dose by approximately 20%.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">During the first weeks the reduction should, at least partially, be compensated by an increase in mealtime insulin, after this period the regimen should be adjusted individually. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">With improved metabolic control and resulting increase in insulin sensitivity a further adjustment in dose regimen may become necessary. Dose adjustment may also be required, for example, if the patient's weight or life-style changes, change of timing of insulin dose or other circumstances arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see section 4.4). </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with ABASAGLAR.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR is administered subcutaneously.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR should not be administered intravenously. The prolonged duration of action of insulin glargine is dependent on its injection into subcutaneous tissue. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">There are no clinically relevant differences in serum insulin or glucose levels after abdominal, deltoid or thigh administration of insulin glargine. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4.8).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR must not be mixed with any other insulin or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">For further details on handling, see section 6.6.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Before using ABASAGLAR solution for injection in prefilled pen, the instructions for use included in the package leaflet must be read carefully (see section 6.6).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="Default"><i><u><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>KwikPen</span></u></i></p><p class="Default"><i><u><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'></span></u></i></p><p class="Default"><a name="_Hlk46321788"><span style='font-size:11.0pt; font-family:"Times New Roman",serif'>The</span></a><span style='font-size:11.0pt; font-family:"Times New Roman",serif'>K</span><span lang="BG" style='font-size: 11.0pt;font-family:"Times New Roman",serif'>wik</span><span style='font-size: 11.0pt;font-family:"Times New Roman",serif'>P</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>en is </span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>registered</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'> in two presentations. One <a name="_Hlk46321308">delivers 1 60 units</a> in steps of</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>1 unit in a single injection</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'> and the other</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'> delivers 1  </span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>8</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>0 units in steps of 1 unit in a single injection. The needed dose is dialled in units. The number of units is shown in the dose window of the pen</span><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'>. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"><i><u><span lang="EN-GB">Tempo Pen</span></u></i></p><p class="MsoNormal" style="line-height:normal"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal"><a name="_Hlk38964026"><span lang="EN-GB">The Tempo Pen delivers 1  80 units in steps of 1 unit in a single injection. The needed dose is dialled in units. The number of units is shown in the dose window of the pen.</span></a></p><p class="mdTblEntry" style="line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">The Tempo Pen can be used with the optional transfer module Tempo Smart Button (see section 6.6).</span></p><p class="mdTblEntry" style="line-height:normal"></p><p class="MsoNormal"><a name="_Hlk32916492"><span lang="EN-GB">As with any insulin injection, when using the Tempo Pen, Smart Button and the mobile application,</span></a><span lang="EN-GB">the patient should be instructed to check their blood sugar levels when considering or making decisions about another injection if they are unsure how much they have injected.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><u><span lang="EN-GB"></span></u></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Traceability"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In order to improve the traceability of biological medicinal products, the name and the batch number of the administered medicinal product should be clearly recorded.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Diabetic ketoacidosis</span></u></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, regular insulin administered intravenously is recommended in such cases. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Insulin requirements and dose adjustments</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In case of insufficient glucose control or a tendency to hyperglycaemic or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, longacting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Hypoglycaemia</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The time of occurrence of hypoglycaemia depends on the action profile of the insulins used and may, therefore, change when the treatment regimen is changed. Due to more sustained basal insulin supply with insulin glargine, less nocturnal but more early morning hypoglycaemia can be expected.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Particular caution should be exercised, and intensified blood glucose monitoring is advisable in patients in whom hypoglycaemic episodes might be of particular clinical relevance, such as in patients with significant stenoses of the coronary arteries or of the blood vessels supplying the brain (risk of cardiac or cerebral complications of hypoglycaemia) as well as in patients with proliferative retinopathy, particularly if not treated with photocoagulation (risk of transient amaurosis following hypoglycaemia). </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Patients should be aware of circumstances where warning symptoms of hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be changed, be less pronounced or be absent in certain risk groups. These include patients:</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        in whom glycaemic control is markedly improved,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        in whom hypoglycaemia develops gradually,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        who are elderly,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        after transfer from animal insulin to human insulin,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        in whom an autonomic neuropathy is present,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        with a long history of diabetes,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        suffering from a psychiatric illness,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        receiving concurrent treatment with certain other medicinal products (see section 4.5).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Such situations may result in severe hypoglycaemia (and possibly loss of consciousness) prior to the patient's awareness of hypoglycaemia.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The prolonged effect of subcutaneous insulin glargine may delay recovery from hypoglycaemia.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">If normal or decreased values for glycated haemoglobin are noted, the possibility of recurrent, unrecognised (especially nocturnal) episodes of hypoglycaemia must be considered. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Adherence of the patient to the dose and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia. Factors increasing the susceptibility to hypoglycaemia require particularly close monitoring and may necessitate dose adjustment. These include:</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        change in the injection area,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        improved insulin sensitivity (e.g., by removal of stress factors),</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        unaccustomed, increased or prolonged physical activity,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        intercurrent illness (e.g. vomiting, diarrhoea),</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        inadequate food intake,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        missed meals,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        alcohol consumption,</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        certain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or adrenocortical insufficiency),</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"><span lang="EN-GB">-        concomitant treatment with certain other medicinal products.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB">Injection technique</span></u></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Intercurrent illness</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Intercurrent illness requires intensified metabolic monitoring. In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased. Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food, or are vomiting etc. and they must never omit insulin entirely. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Insulin antibodies</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see section 5.1).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Medication errors</span></u></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Medication errors have been reported in which other insulins, particularly shortacting insulins, have been accidentally administered instead of insulin glargine. Insulin label must always be checked before each injection to avoid medication errors between ABASAGLAR pre-filled pen as well as other insulins.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><u><span lang="EN-GB">Combination of ABASAGLAR with pioglitazone</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB">Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and ABASAGLAR is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Tempo Pen</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The Tempo Pen contains a magnet (see section 6.5) that may interfere with the functions of an implantable electronic medical device, such as a pacemaker. T</span><span lang="EN-GB">he magnetic field extends to approximately 1.5 cm</span><span lang="EN-GB">.</span></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB">Sodium content</span></u></p><p class="MsoNormal" style="line-height:normal"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially sodiumfree.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">A number of substances affect glucose metabolism and may require dose adjustment of insulin glargine.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Substances that may enhance the blood-glucoselowering effect and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates, somatostatin anologues and sulphonamide antibiotics. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens, progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood-glucose lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Pregnancy"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Animal data do not indicate reproductive toxicity. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The use of ABASAGLAR may be considered during pregnancy, if clinically needed.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy to prevent adverse outcomes associated with hyperglycaemia. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Immediately after delivery, insulin requirements decline rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose control is essential. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Breast-feeding"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">It is unknown whether insulin glargine is excreted in human milk. No metabolic effects of ingested insulin glargine on the breastfed newborn/infant are anticipated since insulin glargine as a peptide is digested into amino acids in the human gastrointestinal tract. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Breast-feeding women may require adjustments in insulin dose and diet. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Fertility"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Animal studies do not indicate direct harmful effects with respect to fertility.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be considered whether it is advisable to drive or operate machines in these circumstances.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Summary of safety profile</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Hypoglycaemia (very common), in general the most frequent adverse reaction of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement (see section 4.4).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><u><span lang="EN-GB">Tabulated list of adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">The following related adverse reactions from clinical trials are listed below as MedDRA preferred term by system organ class and in order of decreasing incidence (very common: 1/10; common: 1/100 to &lt;1/10; uncommon: 1/1,000 to &lt;1/100; rare: 1/10,000 to &lt;1/1,000; very rare: &lt;1/10,000 <a name="_Hlk23422201"><span style="color:black">and not known (cannot be estimated from the available data</span></a>).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:12.5pt;border-collapse:collapse;border:none" width="99%"> <tr style="height:16.75pt"> <td colspan="2" style="width:22.24%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="22%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><b><span lang="EN-GB">MedDRA system organ classes</span></b></p> </td> <td colspan="2" style="width:15.2%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="15%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><b><span lang="EN-GB">Very common</span></b></p> </td> <td style="width:12.28%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="12%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><b><span lang="EN-GB">Common</span></b></p> </td> <td style="width:15.18%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="15%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><b><span lang="EN-GB">Uncommon</span></b></p> </td> <td style="width:11.02%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="11%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><b><span lang="EN-GB">Rare</span></b></p> </td> <td style="width:11.08%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="11%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><b><span lang="EN-GB">Very rare</span></b></p> </td> <td style="width:13.0%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="13%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><b><span lang="EN-GB">Not known</span></b></p> </td> </tr> <tr style="height:16.3pt"> <td colspan="8" style="width:87.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Immune system disorders </span></b></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:16.75pt"> <td colspan="2" style="width:22.24%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="22%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Allergic reactions</span></p> </td> <td colspan="2" style="width:15.2%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:12.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:15.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">X</span></p> </td> <td style="width:11.08%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> </tr> <tr style="height:16.75pt"> <td colspan="8" style="width:87.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Metabolism and nutrition disorders</span></b></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.75pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:16.3pt"> <td colspan="2" style="width:22.24%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="22%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Hypoglycaemia</span></p> </td> <td colspan="2" style="width:15.2%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">X</span></p> </td> <td style="width:12.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:15.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.08%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> </tr> <tr style="height:16.3pt"> <td colspan="8" style="width:87.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Nervous system disorders</span></b></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.3pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:11.0pt"> <td colspan="2" style="width:22.24%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="22%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Dysgeusia</span></p> </td> <td colspan="2" style="width:15.2%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:12.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:15.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.08%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">X</span></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> </tr> <tr style="height:11.0pt"> <td colspan="8" style="width:87.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Eyes disorders</span></b></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.0pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td colspan="2" style="width:22.24%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="22%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Visual impairment </span></p> </td> <td colspan="2" style="width:15.2%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:12.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:15.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">X</span></p> </td> <td style="width:11.08%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td colspan="2" style="width:22.24%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="22%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Retinopathy</span></p> </td> <td colspan="2" style="width:15.2%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:12.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:15.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">X</span></p> </td> <td style="width:11.08%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td colspan="8" style="width:87.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></b></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td colspan="2" style="width:22.24%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="22%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Lipohypertrophy</span></p> </td> <td colspan="2" style="width:15.2%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:12.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">X</span></p> </td> <td style="width:15.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.08%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td colspan="2" style="width:22.24%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="22%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Lipoatrophy</span></p> </td> <td colspan="2" style="width:15.2%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:12.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:15.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">X</span></p> </td> <td style="width:11.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.08%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td colspan="2" style="width:22.24%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="22%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Cutaneous amyloidosis</span></p> </td> <td colspan="2" style="width:15.2%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:12.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:15.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.08%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:13.0%;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">X</span></p> </td> </tr> <tr style="height:5.75pt"> <td colspan="8" style="width:87.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Musculoskeletal and connective tissue disorders</span></b></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td colspan="2" style="width:22.24%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="22%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Myalgia</span></p> </td> <td colspan="2" style="width:15.2%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:12.28%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:15.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.08%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">X</span></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td colspan="8" style="width:87.0%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="87%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">General disorders and administration site conditions</span></b></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td style="width:22.1%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="22%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Injection site reactions</span></p> </td> <td colspan="2" style="width:15.2%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td colspan="2" style="width:12.42%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">X</span></p> </td> <td style="width:15.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.08%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> </tr> <tr style="height:5.75pt"> <td style="width:22.1%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="22%"> <p class="MsoNormal" style="margin-bottom:2.55pt;line-height:normal;page-break-after:   avoid"><span lang="EN-GB">Oedema</span></p> </td> <td colspan="2" style="width:15.2%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td colspan="2" style="width:12.42%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="12%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:15.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="15%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:11.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">X</span></p> </td> <td style="width:11.08%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="11%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> <td style="width:13.0%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:5.75pt" valign="top" width="13%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal;   page-break-after:avoid"></p> </td> </tr> <tr height="0"> <td style="border:none" width="155"></td> <td style="border:none" width="1"></td> <td style="border:none" width="106"></td> <td style="border:none" width="1"></td> <td style="border:none" width="86"></td> <td style="border:none" width="106"></td> <td style="border:none" width="77"></td> <td style="border:none" width="78"></td> <td style="border:none" width="91"></td> </tr> </table><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Description of selected adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Metabolism and nutrition disorders</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may be life-threatening. In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter-regulation. Generally, the greater and more rapid the decline in blood glucose, the more marked is the phenomenon of counter-regulation and its symptoms.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Immune system disorders</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Immediate-type allergic reactions to insulin are rare. Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angio-oedema, bronchospasm, hypotension and shock, and may be life-threatening.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Eyes disorders</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">A marked change in glycaemic control may cause temporary visual impairment, due to temporary alteration in the turgidity and refractive index of the lens.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy. However, intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy. In patients with proliferative retinopathy, particularly if not treated with photocoagulation, severe hypoglycaemic episodes may result in transient amaurosis.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal"><span lang="EN-GB">Lipodystrophy and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (</span><span lang="EN-GB">see section 4.4).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><i><u><span lang="EN-GB">General disorders and administration site conditions</span></u></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><span lang="EN-GB">Injection site reactions include redness, pain, itching, hives, swelling, or inflammation. Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Rarely, insulin may cause sodium retention and oedema particularly if previously poor metabolic control is improved by intensified insulin therapy.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><b></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In general, the safety profile for children and adolescents ( 18 years of age) is similar to the safety profile for adults. The adverse reaction reports received from post marketing surveillance included relatively more frequent injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) in children and adolescents ( 18 years of age) than in adults. Clinical study safety data are not available for children under 2 years.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><b></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Reporting of suspected adverse reactions"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="background: lightgrey">the national reporting system listed in </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="color:windowtext;background:lightgrey">Appendix V</span></a></span><span lang="EN-GB">.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Symptoms</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Insulin overdose may lead to severe and sometimes long-term and life-threatening hypoglycaemia. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Management</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Mild episodes of hypoglycaemia can usually be treated with oral carbohydrates. Adjustments in dose of the medicinal product, meal patterns, or physical activity may be needed. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Pharmacotherapeutic group: Drugs used in diabetes, insulins and analogues for injection, long-acting. ATC Code: A10AE04.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">ABASAGLAR is a biosimilar medicinal product. Detailed information is available on the website of the European Medicines Agency </span><span lang="EN-GB"><a href="http://www.ema.europa.eu"><span style="color:windowtext">http://www.ema.europa.eu</span></a></span><span lang="EN-GB">.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Mechanism of action"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH. It is completely soluble at the acidic pH of the ABASAGLAR injection solution (pH 4). After injection into the subcutaneous tissue, the acidic solution is neutralised leading to formation of micro-precipitates from which small amounts of insulin glargine are continuously released, providing a smooth, peakless, predictable concentration/time profile with a prolonged duration of action.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Insulin glargine is metabolised into 2 active metabolites M1 and M2 (see section 5.2).</span></p><p class="MsoNormal" style="line-height:normal"> </p><p class="MsoNormal" style="line-height:normal"><i><u><span lang="EN-GB">Insulin receptor binding</span></u></i></p><p class="MsoNormal" style="line-height:normal"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal"><i><span lang="EN-GB">In vitro</span></i><span lang="EN-GB"> studies indicate that the affinity of insulin glargine and its metabolites M1 and M2 for the human insulin receptor is similar to the one of human insulin.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">IGF-1 receptor binding: The affinity of insulin glargine for the human IGF-1 receptor is approximately 5 to 8-fold greater than that of human insulin (but approximately 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1 receptor with slightly lower affinity compared to human insulin.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The total therapeutic insulin concentration (insulin glargine and its metabolites) found in type 1 diabetic patients was markedly lower than what would be required for a half maximal occupation of the IGF-1 receptor and the subsequent activation of the mitogenic-proliferative pathway initiated by the IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may activate the mitogenic-proliferative pathway; however, the therapeutic concentrations found in insulin therapy, including in ABASAGLAR therapy, are considerably lower than the pharmacological concentrations required to activate the IGF-1 pathway. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Pharmacodynamic effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis and enhances protein synthesis.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In clinical pharmacology studies, intravenous insulin glargine and human insulin have been shown to be equipotent when given at the same doses. As with all insulins, the time course of action of insulin glargine may be affected by physical activity and other variables.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In euglycaemic clamp studies in healthy subjects or in patients with type 1 diabetes, the onset of action of subcutaneous insulin glargine was slower than with human NPH insulin, its effect profile was smooth and peakless, and the duration of its effect was prolonged.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The following graph shows the results from a study in patients:</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">Figure 1: </span></b><b>Activity profile in patients with type</b><b>1 diabetes</b></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"></p><p align="right" class="MsoNormal" style="text-align:right;line-height:normal; page-break-after:avoid"><span style="position:absolute;z-index:251686912; left:0px;margin-left:-6px;margin-top:15px;width:652px;height:274px"><img height="274" src="#image3" width="652"/></span><span style="position:absolute;z-index:251684864;left:0px;margin-left:161px; margin-top:233px;width:159px;height:39px"><img alt="Time (h) after s.c injection" height="39" src="#image4" width="159"/></span><span lang="EN-GB"><img border="0" height="286" id="Picture 2" src="#image5" width="590"/></span></p><p class="MsoNormal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">* Determined as amount of glucose infused to maintain constant plasma glucose levels (hourly mean values)</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The longer duration of action of subcutaneous insulin glargine is directly related to its slower rate of absorption and supports once daily administration. The time course of action of insulin and insulin analogues such as insulin glargine may vary considerably in different individuals or within the same individual</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical study, symptoms of hypoglycaemia or counter-regulatory hormone responses were similar after intravenous insulin glargine and human insulin both in healthy volunteers and patients with type 1 diabetes.</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Clinical safety and efficacy</span></u></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In clinical studies, antibodies that cross-react with human insulin and insulin glargine were observed with the same frequency in both NPH-insulin and insulin glargine treatment groups.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Effects of insulin glargine (once daily) on diabetic retinopathy were evaluated in an open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography. No significant difference was seen in the progression of diabetic retinopathy when insulin glargine was compared to NPH insulin.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The ORIGIN (Outcome Reduction with Initial Glargine INtervention) study was a multicenter, randomised, 2x2 factorial design study conducted in 12,537 participants at high cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus treated with 1 antidiabetic oral agent (88% of participants). Participants were randomised (1:1) to receive insulin glargine (n=6,264), titrated to reach FPG 95 mg/dL (5.3 mM), or standard care (n=6,273).</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The first co-primary efficacy outcome was the time to the first occurrence of CV death, nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary efficacy outcome was the time to the first occurrence of any of the first co-primary events, or revascularisation procedure (coronary, carotid, or peripheral), or hospitalisation for heart failure.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Secondary endpoints included all-cause mortality and a composite microvascular outcome.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Insulin glargine did not alter the relative risk for CV disease and CV mortality when compared to standard of care. There were no differences between insulin glargine and standard care for the two co-primary outcomes; for any component endpoint comprising these outcomes; for all-cause mortality; or for the composite microvascular outcome.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Mean dose of insulin glargine by study end was 0.42 U/kg. At baseline, participants had a median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9 to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care group throughout the duration of follow-up. The rates of severe hypoglycaemia (affected participants per 100 participant years of exposure) were 1.05 for insulin glargine and 0.30 for standard care group and the rates of confirmed non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard care group. Over the course of this 6-year study, 42% of the insulin glargine group did not experience any hypoglycaemia. </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At the last on-treatment visit, there was a mean increase in body weight from baseline of 1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the standard care group.</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a randomised, controlled clinical study, paediatric patients (age range 6 to 15 years) with type 1 diabetes (n=349) were treated for 28 weeks with a basal-bolus insulin regimen where regular human insulin was used before each meal. Insulin glargine was administered once daily at bedtime and NPH human insulin was administered once or twice daily. Similar effects on glycohaemoglobin and the incidence of symptomatic hypoglycaemia were observed in both treatment groups, however fasting plasma glucose decreased more from baseline in the insulin glargine group than in the NPH group. There was less severe hypoglycaemia in the insulin glargine group as well. One hundred forty three of the patients treated with insulin glargine in this study continued treatment with insulin glargine in an uncontrolled extension study with mean duration of follow-up of 2 years. No new safety signals were seen during this extended treatment with insulin glargine.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">A crossover study comparing insulin glargine plus lispro insulin to NPH plus regular human insulin (each treatment administered for 16 weeks in random order) in 26 adolescent type 1 diabetic patients aged 12 to 18 years was also performed. As in the paediatric study described above, fasting plasma glucose reduction from baseline was greater in the insulin glargine group than in the NPH group. HbA<sub>1c</sub> changes from baseline were similar between treatment groups; however blood glucose values recorded overnight were significantly higher in the insulin glargine/ lispro group than the NPH/regular group, with a mean nadir of 5.4 mM vs. 4.1 mM. Correspondingly, the incidences of nocturnal hypoglycaemia were 32 % in the insulin glargine / lispro group vs. 52 % in the NPH / regular group.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">A 24-week parallel group study was conducted in 125 children with type 1 diabetes mellitus aged 2 to 6 years, comparing insulin glargine given once daily in the morning to NPH insulin given once or twice daily as basal insulin. Both groups received bolus insulin before meals. The primary aim of demonstrating non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and there was a trend to an increase of hypoglycaemic events with insulin glargine [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)]. Glycohaemoglobin and glucose variabilities were comparable in both treatment groups. No new safety signals were observed in this trial.</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Absorption"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In healthy subjects and diabetic patients, insulin serum concentrations indicated a slower and much more prolonged absorption and showed a lack of a peak after subcutaneous injection of insulin glargine in comparison to human NPH insulin. Concentrations were thus consistent with the time profile of the pharmacodynamic activity of insulin glargine. Figure 1 above shows the activity profiles over time of insulin glargine and NPH insulin. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Insulin glargine injected once daily will reach steady state levels in 2-4 days after the first dose. </span></p><p class="MsoNormal" style="line-height:normal"> </p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Biotransformation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">After subcutaneous injection in diabetic patients, insulin glargine is rapidly metabolised at the carboxyl terminus of the Beta chain with formation of two active metabolites M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is the metabolite M1. The exposure to M1 increases with the administered dose of insulin glargine.</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with insulin glargine is principally based on exposure to M1. Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of insulin glargine.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Elimination"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">When given intravenously the elimination half-life of insulin glargine and human insulin were comparable. </span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"> </p><p style="margin:0in"><u><span lang="EN-GB" style="font-size:11.0pt">Special populations</span></u></p><p style="margin:0in"></p><p style="margin:0in"><span lang="EN-GB" style="font-size:11.0pt">In clinical studies, subgroup analyses based on age and gender did not indicate any difference in safety and efficacy in insulin glargine-treated patients compared to the entire study population.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB">Paediatric population</span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Pharmacokinetics in children aged 2 to less than 6 years with type 1 diabetes mellitus was assessed in one clinical study (see section 5.1). Plasma trough levels of insulin glargine and its main M1 and M2 metabolites were measured in children treated with insulin glargine, revealing plasma concentration patterns similar to adults, and providing no evidence for accumulation of insulin glargine or its metabolites with chronic dosing.</span></p><p class="MsoNormal" style="margin-right:-.1pt;line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Zinc oxide</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Metacresol</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Glycerol</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Hydrochloric acid (for pH adjustment)</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Sodium hydroxide (for pH adjustment)</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Water for injections</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">This medicinal product must not be mixed with other medicinal products. </span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p style="margin:0in"><span lang="EN-GB" style="font-size:11.0pt">2 years.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Shelf life after first use </span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The medicinal product may be stored for a maximum of 28 days up to 30C and away from direct heat or direct light. Pens in use must not be stored in the refrigerator. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The pen cap must be put back on the pen after each injection in order to protect from light.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">Before use</span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Store in a refrigerator (2C - 8C).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Do not freeze.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Do not store ABASAGLAR next to the freezer compartment or a freezer pack.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Keep the pre-filled pen in the outer carton in order to protect from light.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB">In use </span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">For storage conditions after first opening of this medicinal product, see section 6.3.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><b><s><span lang="EN-GB"></span></s></b></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"><u><span lang="EN-GB">KwikPen</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">3 mL solution in a cartridge (type 1 colourless glass) with a plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and halobutyl rubber) with aluminium seal. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The cartridge is sealed in a disposable pen injector. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Packs of 5 pre-filled pens and multipacks containing 10 (2 packs of 5) pre-filled pens. </span></p><p class="MsoNormal" style="text-autospace:none"></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB">Tempo Pen</span></u></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">3 mL solution in a cartridge (type 1 colourless glass) with a plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and halobutyl rubber) with aluminium seal. The cartridge is sealed in a disposable pen injector. The Tempo Pen contains a magnet (see section 4.4).</span></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Packs of 5 <a name="_Hlk44087754">pre-filled pens</a> and multipacks containing 10 (2 packs of 5) pre-filled pens</span><span lang="EN-GB">.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Needles are not included in the pack.</span></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal and other handling"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR must not be mixed with any other insulin or medicinal products or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Inspect the cartridge before use. It must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of water-like consistency. Since ABASAGLAR is a solution, it does not require re-suspension before use. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">ABASAGLAR must not be mixed with any other insulin or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Empty pens must never be reused and must be properly discarded. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">To prevent the possible transmission of disease, each pen must be used by one patient only. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins (see section 4.4).</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The patient should be advised to read the instructions for use included in the package leaflet carefully before using ABASAGLAR solution for injection in prefilled pen.</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal"><a name="_Hlk20390276"><u><span lang="EN-GB">Tempo Pen</span></u></a></p><p class="MsoNormal"><u><span lang="EN-GB"></span></u></p><p class="mdTblEntry" style="line-height:normal"><a name="_Hlk38978858"></a><a name="_Hlk45820494"><span lang="EN-GB" style="font-size:11.0pt">The Tempo Pen is designed to work with the Tempo Smart Button. </span></a><span lang="EN-GB" style="font-size:11.0pt">The Tempo Smart Button is an optional product that can be attached to the Tempo Pen dose knob and aids in transmitting Abasaglar dose information from the Tempo Pen to a compatible mobile application. The Tempo Pen injects insulin with or without the Tempo Smart Button attached. To transmit data to the mobile application, follow the instructions provided with the Tempo Smart Button and the instructions with the mobile application. </span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid;text-autospace: none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBER(S)"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">EU/1/14/944/007</span></p><p class="MsoNormal" style="line-height:normal"><span lang="ES-TRAD">EU/1/14/944/008</span></p><p class="MsoNormal" style="line-height:normal"><span lang="ES-TRAD">EU/1/14/944/012</span></p><p class="MsoNormal" style="line-height:normal"><span lang="ES-TRAD">EU/1/14/944/013</span></p><p class="MsoNormal"><span lang="ES-TRAD" style="color:black">EU/1/14/944/014</span></p><p class="MsoNormal"><span lang="ES" style="color:black">EU/1/14/944/015</span></p><p class="MsoNormal" style="line-height:normal"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Date of first authorisation: 9 September 2014</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Date of latest renewal: 25 July 2019</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;text-autospace:none"></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency </span><span lang="EN-GB"><a href="http://www.ema.europa.eu"><span style="color:windowtext">http://www.ema.europa.eu</span></a></span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
</section>
							<!-- sections can repeat as necessary -->
						</Composition>
					</resource>
				</entry>
				
			</Bundle>
		</resource>
	</entry>
</Bundle>